|
15 February 2008
A new cataract gene's location and defect in the coding region was discovered.
|
01 February 2008
By:
Cheryl Guttman
Topical nonsteroidal anti-inflammatory drugs often are administered for off-label purposes to patients who are undergoing cataract surgery, but surgeons should consider the cost, the risks, and the evidence available to support such use.
|
10 December 2007
By:
Fedra Pavlou, Jorge L. Alio, MD, PhD, Professor H. Burkhard Dick, MD, PhD, Christoph Faschinger, MD, Dr Alessandro Franchini, Pavel Kuchynka, MD, Carlos Verges, MD, PhD
A look back at what happened in the fields of cataract & refractive surgery in 2007 and what we can look forward to in 2008.
|
01 October 2007
By:
Fernando Araujo-Gomes
I am sure many surgeons are familiar with these complaints and for those wishing to switch to bimanual cataract surgery, there are certainly a number of initial difficulties that must first be overcome.
|
01 September 2007
By:
Guy Sallet, MD
Guy Sallet talks us through a new "viscoless" procedure and outlines the advantages of such surgery, which include fewer IOP spikes, shortened surgery time and less microincision blockages.
|
01 September 2007
By:
Carlo Cagini
The development of small sutureless incisions in cataract surgery has led to an increased interest in the use of topical ocular anaesthesia. Topical administration of anaesthetic agents is a very simple technique that can achieve good anaesthesia and eliminate potentially sight-threatening complications related to peribulbar or retrobulbar anaesthesia, such as haemorrhaging, optic nerve trauma or globe perforation.
|
01 September 2007
By:
John J. DeStafeno, MD, John P. Berdahl, MD, Terry Kim, MD
Overall, this study showed that wound integrity was maintained in eyes receiving microcoaxial phaco, while all eyes receiving bimanual phaco had spontaneous wound leakage, increased wound hydration, penetration of ink particles into the anterior chamber and some degree of corneal wound burn
|
01 September 2007
By:
Dr Wolfram Wehner
MICS is no longer just a more modern and innovative therapeutic option for cataract; it is also the best choice when offering refractive solutions.
|
01 June 2007
By:
S.M. Mojon-Azzi, D.S. Mojon
Long waiting times have become a progressively important issue, particularly in countries with publicly funded systems.
|
|
